Impact of Quality of Life in the Patients With Sleep Disturbance From Low Anterior Resection Syndrome in Advanced Rectal Cancer Patients
1 other identifier
observational
100
1 country
1
Brief Summary
The preservation surgery of the anal sphincter has become a standard procedure for the treatment of rectal cancer and is now possible even when the tumor is close to the anus, thanks to the advancement of surgical techniques. This procedure allows patients to avoid a permanent artificial anus and enables them to evacuate through the anus, maintaining the continuity of the intestine, making it a highly preferred surgical option. Additionally, advancements in tumor treatments have led to improved long-term survival rates. However, this anal sphincter preservation surgery inevitably can cause functional abnormalities in the rectum, and around 90% of patients experience changes in bowel habits after surgery. The characteristic symptoms occurring after rectal cancer surgery, such as diarrhea, urgency of bowel movements, frequent bowel movements, and fecal incontinence, are referred to as Anterior Resection Syndrome (ARS). Particularly, symptoms following low anterior resection surgery for lower rectal cancer are termed Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, persisting up to 1-2 years, with some improvement over time. However, in many patients, LARS can remain a lifelong challenge, significantly impacting their quality of life. Currently, there is no definitive method to treat LARS, and symptom management is achieved through empirical treatment methods or medications. Many patients with LARS experience these symptoms predominantly at night, and it is presumed that their sleep quality is severely compromised, significantly affecting their overall quality of life. However, there is a lack of research on the prevalence of such patients and the appropriate treatments for them.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 26, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2023
CompletedFirst Submitted
Initial submission to the registry
February 4, 2024
CompletedFirst Posted
Study publicly available on registry
February 22, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 29, 2024
CompletedMarch 26, 2024
February 1, 2024
1.8 years
February 4, 2024
March 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).
Insomnia Severity Index Score : Sum of Insomnia Severity Index score
1 Month
Secondary Outcomes (2)
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
1 Month
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29)
1 Month
Study Arms (2)
Insomnia Severity index Grade 0&1
administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
Insomnia Severity index Grade 2&3
administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
Interventions
The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the "last month." The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties.
Eligibility Criteria
Patients who have undergone low anterior resection surgery following progressive rectal cancer without permanent stoma
You may qualify if:
- undergone low anterior resection for progressive rectal cancer
- undergone bowel continence restoration surgery and are between 1 month and 5 years postoperative
- ability to comprehend and participate in the clinical trial
You may not qualify if:
- A history of previous surgery for colorectal cancer
- Recurrent colorectal cancer
- Concomitant metastatic colorectal cancer
- Requiring permanent colostomy
- Underlying conditions not controlled by medical treatment
- Inflammatory bowel disease
- Chronic constipation or diarrhea not controlled by medication before surgery
- Preoperative symptoms of fecal incontinence
- Preoperative symptoms of bowel leakage
- Allergies to the investigational drug
- Deemed unsuitable for participation in the clinical trial by the principal investigator and study staff
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Hospital
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2024
First Posted
February 22, 2024
Study Start
February 26, 2022
Primary Completion
November 30, 2023
Study Completion
February 29, 2024
Last Updated
March 26, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share